Nissay Asset Management Corp Japan Boosts Position in Gilead Sciences, Inc. $GILD

Posted by Francis Steltz on Aug 29th, 2026

Gilead Sciences logo Nissay Asset Management Corp Japan lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 6.4% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 371,019 shares of the biopharmaceutical company’s stock after acquiring an additional 22,333 shares during the quarter. Nissay Asset Management Corp Japan’s holdings in Gilead Sciences were worth $46,875,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in the stock. Aviva PLC raised its holdings in shares of Gilead Sciences by 5.4% in the fourth quarter. Aviva PLC now owns 1,156,738 shares of the biopharmaceutical company’s stock valued at $141,978,000 after buying an additional 59,782 shares during the last quarter. Life Cycle Investment Partners Ltd bought a new stake in Gilead Sciences during the 4th quarter worth about $1,418,000. Bank of Nova Scotia acquired a new stake in Gilead Sciences in the 2nd quarter valued at about $100,056,000. OMERS ADMINISTRATION Corp bought a new position in shares of Gilead Sciences in the second quarter worth about $55,754,000. Finally, Harvest Fund Management Co. Ltd raised its stake in shares of Gilead Sciences by 14.4% in the fourth quarter. Harvest Fund Management Co. Ltd now owns 106,526 shares of the biopharmaceutical company’s stock worth $13,075,000 after acquiring an additional 13,385 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $155.00 price target on shares of Gilead Sciences in a research note on Wednesday, August 5th. Leerink Partners cut shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $146.00 to $127.00 in a research report on Tuesday, July 21st. Daiwa Securities Group reduced their price objective on Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating on the stock in a report on Tuesday, May 19th. HSBC upgraded Gilead Sciences from a “hold” rating to a “buy” rating and increased their price objective for the company from $133.00 to $155.00 in a research report on Monday, July 6th. Finally, Weiss Ratings cut Gilead Sciences from a “buy (b-)” rating to a “hold (c-)” rating in a research note on Tuesday, August 11th. Twenty-four equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and an average price target of $158.04.

Get Our Latest Stock Analysis on GILD

Insider Activity at Gilead Sciences

In other news, CEO Daniel Patrick O’day sold 15,000 shares of the stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $130.31, for a total value of $1,954,650.00. Following the transaction, the chief executive officer owned 592,133 shares of the company’s stock, valued at $77,160,851.23. This represents a 2.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $138.36, for a total value of $415,080.00. Following the completion of the transaction, the chief financial officer owned 165,646 shares in the company, valued at $22,918,780.56. This represents a 1.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 105,000 shares of company stock worth $14,238,120. 0.30% of the stock is owned by company insiders.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

Positive Sentiment: The FDA approved Bixlenvo, a once-daily single-tablet regimen combining bictegravir and lenacapavir for virologically suppressed adults with HIV. It is the first and only single-tablet option for patients on complex regimens who cannot use currently available alternatives, potentially expanding Gilead’s HIV franchise and supporting its longer-term lenacapavir strategy. Reuters FDA approval article
Positive Sentiment: The European Commission approved Trodelvy plus Keytruda for certain first-line metastatic triple-negative breast cancer patients, strengthening Gilead’s oncology portfolio and adding a potential growth opportunity outside its core HIV business. EU Trodelvy approval article
Neutral Sentiment: Analysts remain broadly constructive, with a consensus “Moderate Buy” rating and an average price target of approximately $158. However, GILD’s strong multi-year advance may have raised expectations and limited the immediate upside from the Bixlenvo approval. Gilead valuation article
Negative Sentiment: Director Anthony Welters sold 18,000 shares worth about $2.68 million, reducing his position by roughly 58%. The sale occurred under a pre-arranged Rule 10b5-1 plan, making it a limited bearish signal, but it may still weigh modestly on investor sentiment. SEC insider transaction filing

Gilead Sciences Stock Down 2.1%

Shares of NASDAQ GILD opened at $145.68 on Friday. The firm has a market capitalization of $180.64 billion, a PE ratio of -54.56 and a beta of 0.32. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03. Gilead Sciences, Inc. has a 1 year low of $108.46 and a 1 year high of $157.29. The firm’s 50-day moving average is $134.25 and its 200-day moving average is $136.62.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last posted its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, topping analysts’ consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The business had revenue of $7.80 billion during the quarter, compared to the consensus estimate of $7.40 billion. During the same period in the previous year, the firm posted $2.01 earnings per share. Gilead Sciences’s revenue for the quarter was up 10.6% compared to the same quarter last year. Equities analysts expect that Gilead Sciences, Inc. will post -0.5 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th will be issued a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Gilead Sciences’s payout ratio is currently -122.85%.

About Gilead Sciences

(Free Report)

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.